Word: ipos
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...games for cell phones. "I wanted to be the first to do something, succeed at it and, ultimately, dominate," she says. And dominate she does. Revenue reached a target of $4.2 million in the first half, Park says, and she expects sales to rocket up 650% this year. An IPO is planned...
...keyword, and you're there. Google delivers more than 200 million results daily, thanks to its hyperaccurate algorithms. But there's no such thing as a free search; behind that text-only interface is a serious business edging toward what Wall Street hopes will be a new tech mega-IPO. Omid Kordestani, Google's senior vice president of worldwide sales and field operations, is fast turning the privately held company into a maniacally profitable outfit. His efforts have transformed the world's top search destination into online advertising's hottest property--scoring more than 100,000 advertisers in just...
...might have gone too far, but euro-zone countries should feel free to give breaks of their own. "Governments should have some control over the economy," Stewart argues. "If they choose to run very large deficits, it's not a huge problem." Now loosen that belt. Lights, Camera, IPO Want a piece of the movies? Los Angeles-based Civilian Pictures is offering 900,000 shares in an upcoming picture Billy Dead. At $8.75 a pop, the firm hopes to attract over $7 million to make the murder mystery...
...budgets into an industry that has more hype than earnings in its bloodstream. Mullen's vision didn't immediately play well with biotech investors, many of whom prefer the promise of blowout growth to steady profits. Shares of both companies dropped sharply. Biotech's allure since the benchmark Genentech ipo 23 years ago has been its promise to deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's; compared to that, budgetary discipline seems pretty dull. Yet with an exhaustingly long list of failed products and failed companies in its brief past, the biotech industry each year...
...whom prefer the promise of blowout growth to steady profits. Shares of both companies dropped sharply. Who needs another giant drug company pumping out me-too pills, focusing on stuff it already makes and pinching pennies to deliver a steady income? Biotech's allure since the benchmark Genentech IPO 23 years ago has been its promise to deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's. Yet with an exhaustingly long list of failed products and failed companies in its brief past, the industry each year grows closer to losing sway with the moneymen who fund...